[go: up one dir, main page]

CL2022001583A1 - Derivados espiráncos sustituidos de cadena lineal - Google Patents

Derivados espiráncos sustituidos de cadena lineal

Info

Publication number
CL2022001583A1
CL2022001583A1 CL2022001583A CL2022001583A CL2022001583A1 CL 2022001583 A1 CL2022001583 A1 CL 2022001583A1 CL 2022001583 A CL2022001583 A CL 2022001583A CL 2022001583 A CL2022001583 A CL 2022001583A CL 2022001583 A1 CL2022001583 A1 CL 2022001583A1
Authority
CL
Chile
Prior art keywords
spiranchic
derivatives
straight
chain substituted
protein
Prior art date
Application number
CL2022001583A
Other languages
English (en)
Inventor
Yanping Xu
Vineet Pande
Wei Cai
Xuedong Dai
Olivier Alexis Georges Querolle
Johannes Wilhelmus John F Thuring
Yingtao Liu
Lianzhu Liu
Liqiang Fu
Ming Li
Lichao Fang
Xiangjun Deng
Qiwu Zhao
Kangying Li
Alicia Tee Fuay Ng
Nicolas Freddy J Darville
Edward Cleator
Gregor Thomas Urbanietz
William Marc Maton
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2022001583A1 publication Critical patent/CL2022001583A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
CL2022001583A 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal CL2022001583A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04

Publications (1)

Publication Number Publication Date
CL2022001583A1 true CL2022001583A1 (es) 2023-02-03

Family

ID=76476870

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2022001583A CL2022001583A1 (es) 2019-12-19 2022-06-13 Derivados espiráncos sustituidos de cadena lineal
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal
CL2023001530A CL2023001530A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2023001531A CL2023001531A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal
CL2023001530A CL2023001530A1 (es) 2019-12-19 2023-05-29 Derivados espiráncos sustituidos de cadena lineal

Country Status (21)

Country Link
US (1) US20230142285A1 (es)
EP (1) EP4077312A4 (es)
JP (2) JP7554829B2 (es)
KR (1) KR20220118500A (es)
CN (4) CN118255773A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
PH (1) PH12022551502A1 (es)
TW (1) TWI878414B (es)
UA (1) UA129208C2 (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022237627A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
KR20240006542A (ko) 2021-05-08 2024-01-15 얀센 파마슈티카 엔브이 치환된 스피로 유도체
PE20240593A1 (es) 2021-05-11 2024-03-21 Janssen Pharmaceutica Nv Terapias de combinacion
JP2024519322A (ja) 2021-05-11 2024-05-10 ヤンセン ファーマシューティカ エヌ．ベー． 併用療法
US20230250096A1 (en) 2021-06-01 2023-08-10 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES
JP2024521902A (ja) 2021-06-03 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン
PH12023553300A1 (en) * 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
WO2023098876A1 (en) * 2021-12-03 2023-06-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use
AR130379A1 (es) * 2022-09-02 2024-12-04 Hutchmed Ltd Compuestos de triazina y usos de los mismos
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024218072A1 (en) 2023-04-17 2024-10-24 Janssen Pharmaceutica Nv Combination of a menin-ll1 inhibitor, a dna intercalating agent and a pyrimidine analogue to treat a hematopoietic disorder.
WO2025082444A2 (en) 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US10053477B2 (en) * 2014-07-04 2018-08-21 Qilu Pharmaceutical Co., Ltd. Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
EP3207030A4 (en) * 2014-10-14 2018-06-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白與mll蛋白的相互作用的方法及組合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
KR20180103053A (ko) * 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제
CA3012649A1 (en) 2016-01-26 2017-08-03 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
CN109152784B (zh) 2016-03-16 2021-12-28 库拉肿瘤学公司 经取代的menin-mll抑制剂及使用方法
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
EP3805215A1 (en) * 2016-06-10 2021-04-14 Vitae Pharmaceuticals, LLC Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
LT3512857T (lt) * 2016-09-14 2021-04-12 Janssen Pharmaceutica Nv Menin-mll sąveikos spirobicikliniai inhibitoriai
TWI738864B (zh) 2016-09-14 2021-09-11 比利時商健生藥品公司 Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑
WO2018050684A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
ES2948949T3 (es) 2016-09-16 2023-09-22 Vitae Pharmaceuticals Llc Inhibidores de la interacción menina-MLL
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
JP7628392B2 (ja) 2017-03-24 2025-02-10 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
US11649251B2 (en) * 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor

Also Published As

Publication number Publication date
JP2024138279A (ja) 2024-10-08
EP4077312A4 (en) 2024-01-17
JP2023506530A (ja) 2023-02-16
CN118255774A (zh) 2024-06-28
PE20230162A1 (es) 2023-02-01
IL293965A (en) 2022-08-01
JOP20220154A1 (ar) 2023-01-30
CO2022009085A2 (es) 2022-07-08
PH12022551502A1 (en) 2023-04-24
CL2023001530A1 (es) 2023-11-03
DOP2022000125A (es) 2022-08-31
UA129208C2 (uk) 2025-02-05
UY38988A (es) 2021-06-30
CN114867721A (zh) 2022-08-05
CL2023001531A1 (es) 2023-11-03
JP7554829B2 (ja) 2024-09-20
MX2022007652A (es) 2022-09-23
CR20220346A (es) 2022-10-26
ECSP22054700A (es) 2022-11-30
CA3161045A1 (en) 2021-06-24
EP4077312A1 (en) 2022-10-26
US20230142285A1 (en) 2023-05-11
CN118344372A (zh) 2024-07-16
TWI878414B (zh) 2025-04-01
WO2021121327A1 (en) 2021-06-24
AU2020404305A1 (en) 2022-08-04
TW202138367A (zh) 2021-10-16
KR20220118500A (ko) 2022-08-25
CN118255773A (zh) 2024-06-28

Similar Documents

Publication Publication Date Title
CL2022001583A1 (es) Derivados espiráncos sustituidos de cadena lineal
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
UY39795A (es) DERIVADOS DE FENIL-1H-PIRROLO[2,3-c]PIRIDINA SUSTITUIDOS
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
UY35293A (es) Isotiazoles sustituidos con amino
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.
MX2023013174A (es) Derivados espiro sustituidos.
MX2023013176A (es) Derivados espiro sustituidos.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
TW202525813A (zh) 經取代之直鏈螺環接衍生物
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CL2011000647A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007).
CL2011000645A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; y composicion farmaceutica que los comprende; y su uso en eltratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
CL2011000646A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).